BioMimetic Therapeutics, Inc. to Present at the Wedbush PacGrow Life Sciences Management Access Conference

FRANKLIN, Tenn.--(BUSINESS WIRE)--

BioMimetic Therapeutics, Inc. BMTI announced today that Dr. Samuel Lynch, president and CEO, will provide an update of corporate activities at the Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 15th at 10:20 a.m. Eastern Daylight Time. The presentation will be held in the Gamshoge room at the Le Parker Meridien located in New York, New York.

A live audio webcast of the presentation will be available at http://wsw.com/webcast/wedbush21/bmti/ and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.

About BioMimetic Therapeutics

BioMimetic Therapeutics BMTI is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment^® branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic has received regulatory approvals to market Augment^® Bone Graft in Canada, Australia and New Zealand for use in foot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called Augmatrix^TM Biocomposite Bone Graft.

For further information, contact Kearstin Patterson, senior director of corporate communications, at 615-236-4419.